Sanofi to acquire Blueprint Medicines for $9.1 billion in rare disease expansion
French pharmaceutical giant Sanofi announced Monday that it will acquire U.S.-based Blueprint Medicines for $9.1 billion to strengthen its portfolio in rare immunological diseases.